RACIAL/ETHNIC DIFFERENCES IN USE OF ADJUVANT HORMONAL THERAPY AMONG WOMEN WITH ESTROGEN RECEPTOR-POSITIVE (ER plus ) BREAST CANCER

被引：0
|
作者：
Livaudais, J. [1 ]
Li, C. [1 ]
John, E. [1 ]
Daly, M. [1 ]
Terry, M. [1 ]
Buys, S. [1 ]
Thompson, B. [1 ]
LaCroix, A. [1 ]
Habel, L. [1 ]
Coronado, G. [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
来源：
AMERICAN JOURNAL OF EPIDEMIOLOGY | 2010年 / 171卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [31] Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer
    Owusu, Cynthia
    Buist, Diana S. M.
    Field, Terry S.
    Lash, Timothy L.
    Thwin, Soe Soe
    Geiger, Ann M.
    Quinn, Virginia P.
    Frost, Floyd
    Prout, Marianne
    Yood, Marianne Ulcickas
    Wei, Feifei
    Silliman, Rebecca A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 549 - 555
  • [32] Pharmacogenomic prediction of breast cancer treatment outcome with adjuvant tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer
    Pribylova, O.
    Petruzelka, L. B.
    Argalaczova, S.
    Konopasek, B.
    Drazdakova, J.
    Slanar, O.
    Slanar, O.
    Zima, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
    Pavlovic, R. T.
    Jankovic, S. M.
    Milovanovic, J. R.
    Stefanovic, S. M.
    Folic, M. M.
    Milovanovic, O. Z.
    Mamillapalli, C.
    Milosavljevic, M. N.
    CLINICAL BREAST CANCER, 2019, 19 (06) : E731 - E740
  • [34] Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada
    Djalalov, S.
    Beca, J.
    Amir, E.
    Krahn, M.
    Trudeau, M. E.
    Hoch, J. S.
    CURRENT ONCOLOGY, 2015, 22 (02) : 84 - 96
  • [35] Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men
    Venigalla, Sriram
    Carmona, Ruben
    Guttmann, David M.
    Jain, Varsha
    Freedman, Gary M.
    Clark, Amy S.
    Shabason, Jacob E.
    JAMA ONCOLOGY, 2018, 4 (10)
  • [36] Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in estrogen receptor-positive breast cancer
    Kim, Ji Sun
    Han, Wonshik
    You, Jee Man
    Shin, Hee-Chul
    Ahn, Soo Kyung
    Moon, Hyeong Gon
    Im, Seock-Ah
    Kim, Tae-You
    Cho, Nariya
    Moon, Woo Kyung
    Noh, Dong Young
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer
    Chen, Lu
    Malone, Kathleen E.
    Li, Christopher I.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (09) : 1423 - 1426
  • [38] Bicalutamide Plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer
    Lu, Qianyi
    Xia, Wen
    Lee, Kaping
    Zhang, Jingmin
    Yuan, Huimin
    Yuan, Zhongyu
    Shi, Yanxia
    Wang, Shusen
    Xu, Fei
    ONCOLOGIST, 2020, 25 (01): : 21 - +
  • [39] The Experience of Initiating Oral Adjuvant Treatment for Estrogen Receptor-Positive Breast Cancer
    Flanagan, Jane
    Tetler, Devin
    Winters, Loren
    Post, Kathryn
    Habin, Karleen
    ONCOLOGY NURSING FORUM, 2016, 43 (04) : E143 - E152
  • [40] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
    Gil J.M.
    Rubio-Terrés C.
    del Castillo-Saiz A.
    González P.
    Canorea F.
    Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
12345